title: IL-17A promotes migration and tumor killing capability of B cells in esophageal squamous cell carcinoma.
abstract: We have previously reported that the accumulation of IL-17-producing cells could mediate tumor protective immunity by promoting the migration of NK cells, T cells and dendritic cells in esophageal squamous cell carcinoma (ESCC) patients. However, there were no reports concerning the effect of IL-17A on tumor infiltrating B cells. In this study, we investigated the accumulation of CD20+ B cells in the ESCC tumor nests and further addressed the effect of IL-17A on the migration and cytotoxicity of B cells. There was positive correlation between the levels of CD20+ B cells and IL-17+ cells. IL-17A could promote the ESCC tumor cells to produce more chemokines CCL2, CCL20 and CXCL13, which were associated with the migration of B cells. In addition, IL-17A enhanced the IgG-mediated antibody and complement mediated cytotoxicity of B cells against tumor cells. IL-17A-stimulated B cells gained more effective direct killing capability through enhanced expression of Granzyme B and FasL. The effect of IL-17A on the migration and cytotoxicity of B cells was IL-17A pathway dependent, which could be inhibited by IL-17A inhibitor. This study provides further understanding of the roles of IL-17A in humoral response, which may contribute to the development of novel tumor immunotherapy strategy.
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Lu
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Chengyin
authors.initials: C
authors.lastname: Weng
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Haibo
authors.initials: H
authors.lastname: Mao
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Xisheng
authors.initials: X
authors.lastname: Fang
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Xiaofei
authors.initials: X
authors.lastname: Cao
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Baoxiu
authors.initials: B
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Qinquan
authors.initials: Q
authors.lastname: Gan
authors.affiliation: Department of Experimental Research and State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
authors.forename: Jianchuan
authors.initials: J
authors.lastname: Xia
authors.affiliation: Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510180, China.
authors.forename: Guolong
authors.initials: G
authors.lastname: Liu
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20 / Q000276:immunology / Q000378:metabolism; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology*; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000276:immunology*; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D020381:Interleukin-17; C555450:secukinumab
keywords: B cells; IL-17A; cytotoxicity; esophageal squamous cell carcinoma; recruitment